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Abstract
Tri-ortho-cresyl phosphate (ToCP) is an anti-wear, flame retardant additive used in industrial 
lubricants, hydraulic fluids, and gasoline. The neurotoxic effects of ToCP arise from the liver-
activated metabolite 2-(o-cresyl)-4H-1,3,2-benzodioxaphosphoran-2-one (cresyl saligenin 
phosphate or CBDP), which inhibits esterase enzymes including butyrylcholinesterase (BChE). 
Following BChE adduction, CBDP undergoes hydrolysis to form the aged adduct ortho-cresyl 
phosphoserine (oCP-BChE), thus providing a biomarker of CBDP exposure. Previous studies have 
identified ToCP in aircraft cabin and cockpit air, but assessing human exposure has been hampered 
by the lack of a laboratory assay to confirm exposure. This work presents the development of an 
immunomagnetic-UHPLC-MS/MS method for the quantitation of unadducted BChE and the long-
term CBDP biomarker, oCP-BChE, in human serum. The method has a reportable range from 2.0 
ng/mL to 150 ng/mL, which is consistent with the sensitivity of methods used to detect 
organophosphorus nerve agent protein adducts. The assay demonstrated high intraday and interday 
accuracy (≥ 85%) and precision (RSD ≤ 15%) across the calibration range. The method was 
developed for future analyses of potential human exposure to CBDP. Analysis of human serum 
inhibited in vitro with CBDP demonstrated that the oCP-BChE adduct was stable for at least 72 
hours at 4, 22 and 37 °C. Compared to a previously reported assay, this method requires 75% less 
*Correspondence to: M.D. Carter, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, GA 30341, 
USA. vsm8@cdc.gov. 
Disclaimer
The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for 
Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for 
Disease Control and Prevention, the Public Health Service, or the US Department of Health and Human Services.
Conflict of Interest Disclosure
The authors declare no competing financial interest.
HHS Public Access
Author manuscript
J Mass Spectrom. Author manuscript; available in PMC 2017 December 04.
Published in final edited form as:
J Mass Spectrom. 2015 April ; 50(4): 683–692. doi:10.1002/jms.3576.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
sample volume, reduces analysis time by a factor of 20, and demonstrates a 3-fold improvement in 
sensitivity.
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Introduction
Tricresyl phosphate (TCP) is an organophosphorus additive used in a variety of applications 
including industrial lubricants, hydraulic fluids, and gasoline.1,2 Commercial TCP consists 
of a mixture of ten positional cresyl isomers.3 The mono-, di- and tri-ortho isomers are 
considered to be the most harmful, exhibiting neurotoxic properties.4 Tri-ortho-cresyl 
phosphate (ToCP) has been the most extensively studied ortho isomer.5 Human exposure to 
ToCP has been shown to cause peripheral nerve damage and degeneration of the spinal 
cord.6 The most infamous case of human exposure to ToCP occurred in the United States in 
1930. Consumption of Jamaica Ginger extract (“Jake”) that had been adulterated with ToCP 
led to a condition known as “Jamaica Ginger Paralysis” or “Jake Leg”. Approximately 
50,000 Americans became paralyzed and for most, their paralysis was permanent.7,8 Other 
widespread cases of ToCP poisoning include the consumption of adulterated cooking oil in 
Morocco in 1959 causing the paralysis of approximately 10,000 people, and the most recent 
exposure occurred in 1995 from ingestion of flour tainted with ToCP.9,10
Most industrial uses of TCP were discontinued by 2002; however, it is still used in jet engine 
lubricating oils and hydraulic fluids for its anti-wear and flame retardant properties.11 
Human exposure to ToCP can potentially occur from aircraft bleed air systems which supply 
fresh air throughout the cabin. In a bleed air system, hot, compressed air is pulled from bleed 
ports in the compressor stage of the engine. The air is then cooled and circulated throughout 
the cabin. Engine seals responsible for preventing engine oil from leaking out of the 
compressor zone can malfunction due to age, stress, or wear. If this occurs, engine oil can 
leak out of the compression zone and into the bleed air system.12–14 Previous studies have 
identified the presence of TCP and ToCP in cabin and cockpit air, as well as in the plane’s 
air duct system.14–19 Other reports have focused on the effects of human exposure to 
contaminated cabin air; however, establishing a causal link with ToCP exposure has been 
difficult without an analytical test with the specificity to confirm exposure.13,20,21
The neurotoxic effects from ToCP exposure arise from a liver-activated metabolite rather 
than the parent compound.4 ToCP is metabolized to 2-(o-cresyl)-4H-1,3,2-
benzodioxaphosphoran-2-one (cresyl saligenin phosphate or CBDP) by cytochrome P450 
(Scheme 1).22 CBDP inhibits carboxylesterases, neurotoxic esterase, acetylcholinesterase, 
and butyrylcholinesterase (BChE).23,24 CBDP forms a covalent adduct to the active serine 
site (Ser198) of BChE. A study of the kinetics of adduct formation showed CBDP was a 
potent BChE inhibitor (ki = 1.6 × 108 M−1 min −1).25 As illustrated in Scheme 1, the initial 
adduct formed is a derivative of CBDP and within seconds, aging occurs to produce o-cresyl 
phosphoserine BChE (oCP-BChE).25,26 The resulting +170 amu oCP-BChE adduct was 
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identified in earlier studies following the reaction of CBDP with BChE.24–26 This work 
established oCP-BChE as a potential biomarker for CBDP exposure, and by extension, 
ToCP exposure.
In 2011, Marsillach and coworkers demonstrated that an immunomagnetic separation could 
be used to purify BChE and CBDP-adducted BChE from human serum.24 The 
immunomagnetic separation was later applied to a biomonitoring study of blood collected 
from jet airline passengers. The study monitored for the presence of phosphoserine BChE, a 
generic biomarker of organophosphate exposure, and low exposure levels were reported 
(0.05 to 3% inhibition of plasma BChE).27 The group later developed an assay to detect the 
more specific adduct oCP-BChE. Improvements were also made to the BChE purification 
strategy to reduce sample volume, and electrospray ionization was integrated into the assay 
for improved reproducibility. The assay’s sensitivity was reported as 0.1% oCP-BChE in 
blood; however, the method required lengthy analysis times making it undesirable for high-
throughput analysis.28 Until now, a high-throughput method for the quantitation of oCP-
BChE adducts in clinical samples was unavailable. This work addresses this need and 
presents the development of a high-throughput immunomagnetic UHPLC-MS/MS method 
for the quantitation of oCP-BChE adducts in human blood matrices.
Materials and Methods
Materials
The following synthetic unlabeled and stable isotopically-labeled peptides were obtained 
from TNO (Rijswijk, The Netherlands): BChE: synthetic unlabeled butyrylcholinesterase 
nonapeptide (FGESAGAAS); BChE*: isotopically-labeled BChE nonapeptide (13C9-
FGESAGAAS); oCP-BChE: synthetic unlabeled o-cresyl phosphoserine BChE nonapeptide 
(FGES[oCP]AGAAS); oCP-BChE*: isotopically labeled oCP-BChE nonapeptide (13C9-
FGES[oCP]AGAAS). Peptide amino acid analysis (AAA) was performed at Midwest Bio-
Tech, Inc. (Fishers, IN, USA) and determined to be the following: BChE: 68.0%; BChE*: 
62.3%; oCP-BChE: 53.3%; oCP-BChE*: 75.7%. BChE monoclonal antibodies from clone 
3E8 were purchased from ThermoFisher Affinity Bioreagents (Rockford, IL, USA). HPLC 
grade acetonitrile and deionized water were commercially available from Tedia (Fairfield, 
OH, USA). Formic acid (98%), phosphate buffered saline with Tween 20 (PBST) dry 
powder, dimethyl pimelimidate dihydrochloride (DMP), 0.2 M tris buffered saline (TBS) 
10X concentrate, triethanolamine buffer solution and pepsin from porcine gastric mucosa 
were all purchased from Sigma Aldrich (St. Louis, MO, USA). Dynabeads Protein G were 
obtained from Life Technologies (Carlsbad, CA, USA). KingFisher 96 Flex microplates 
(200 μL), KingFisher 96 tip combs for deep well magnets, KingFisher Flex microliter 
deepwell 96 plates (v-bottom), protein precipitation plates, PCR foil and easy pierce 20 μm 
heat sealing foil were purchased from Fisher Scientific (Rockford, IL, USA). Nonsterile 
MultiScreen HTS HV 0.45 μm opaque filter plates were purchased from EMD Millipore 
(Billerica, MA, USA). Sample concentration used a Porvair MiniVap Blowdown Evaporator 
(Porvair Sciences, Wrexham Wales, UK).
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Stock Solutions and Quality Control (QC) Materials
Synthetic BChE and oCP-BChE peptide calibrators were made following amino acid content 
analysis. Stock solutions were made for each native and isotopically labeled standard (1.00 
mg/mL) in 0.1% formic acid and stored at −70 °C. Native peptide stock solutions were 
combined and diluted in 0.1% formic acid to prepare the eight calibrators. The isotopically 
labeled stock solutions were combined to prepare a single internal standard solution at a 
concentration of 500 ng/mL. Commercial pooled human serum adducted with sarin was 
obtained from Battelle Memorial Institute (Columbus, OH) and served as a matrix blank. 
Sarin-inhibited serum was selected since it was nearly depleted of the unadducted BChE 
protein (back-calculated concentration of BChE in matrix blank serum was below the 
method’s lowest reportable limit), and did not provide interference in the detection of oCP-
BChE calibrators. Quality control (QC) materials for BChE consisted of commercial 
unexposed pooled human serum purchased from TNO for the mid-level QC and synthetic 
BChE peptide spikes into matrix blank serum for low- and high-level BChE QC samples. 
oCP-BChE QC materials consisted of commercial pooled human serum exposed to CBDP 
(TNO) for the low-level QC and synthetic oCP-BChE peptide spikes into matrix blank 
serum for mid- and high-level QC samples. The method QC materials used blood products 
acquired from commercial sources, and the work did not meet the definition of human 
subjects as specified in 45 CFR 46.102 (f). The commercial blood products were screened 
for regulatory pathogens prior to commercial sale.
Convenience Sample Set
A commercial convenience set of 96 individual human sera products were purchased from 
Tennessee Blood Services (Memphis, TN) to evaluate baseline level responses in a 
population in which exposure was not expected. The method used blood products acquired 
from commercial sources, and the work did not meet the definition of human subjects as 
specified in 45 CFR 46.102 (f). The commercial blood products were screened for 
regulatory pathogens prior to commercial sale.
Sample Preparation
Pantazides et al. previously described optimization of the immunomagnetic separation and 
pepsin digest.29 A recovery of approximately 90% of unadducted BChE in serum was 
reported, and similar recoveries were observed for BChE inhibited by organophosphorus 
compounds similar to oCP- (GB and VX). Pepsin digestion parameters were also optimized, 
reporting the BChE protein is fully digested into the nonapeptide (FGES198AGAAS) within 
30 min. Synthetic native and isotopically labeled nonapeptides were stable in these digestion 
conditions for up to 2 hrs.29
Samples were prepared as described by Pantazides et al.29, with a modification made to the 
immunomagnetic purification. Incubation time was reduced to 45 min, which did not alter 
protein extraction efficiency. Briefly, immunomagnetic beads were prepared by applying a 
DynaMag-15 magnet to 2 mL of Dynabeads Protein G. The supernatant was removed, and 
beads were resuspended in 4 mL of PBST. After vortex mixing, the PBST was removed and 
discarded. This wash step was repeated twice. Magnetic beads were then resuspended in 8 
mL PBST and combined with 400 μg of BChE monoclonal antibody. The mixture was 
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subjected to rotation on a Dynal Sample Mixer (speed 20) overnight at room temperature. 
The following day, the supernatant was removed, and 4 mL aliquots of triethanolamine 
buffer were added to the magnetic beads. The triethanolamine buffer was removed and 
discarded, and this wash step was repeated once. A 4 mL aliquot of 27 mg DMP in 5 mL 
triethanolamine buffer was then added to the beads and allowed to rotate (speed 20) on the 
Dynal Sample Mixer for 30 min at room temperature. The supernatant was then removed, 
and magnetic beads were resuspended in 4 mL of TBS. After 15 min of rotation (speed 20) 
at room temperature, TBS was removed and discarded. The magnetic beads were then 
washed twice in 2 mL of PBST. Following two PBST washes, 1.9 mL aliquots of PBST 
were added to the beads. The magnetic bead suspension was stored at 4 °C until use or up to 
3 months.
Following magnetic bead preparation, 125 μL aliquots of serum (either matrix blank, QC for 
BChE, or QC for oCP-BChE) were pipetted into a multiscreen HTS HV 0.45 μm opaque 
filter plate and centrifuged at 3000g for 5 min at 20 °C to remove any fibrous tissue. After 
centrifugation, 75 μL aliquots of filtered serum were transferred to a 96-well KingFisher 
deep-well plate. To wells receiving calibrators, 75 μL aliquots of matrix blank were added to 
address potential matrix effects. A plate containing BChE antibody-conjugated magnetic 
beads was prepared by adding 50 μL aliquots of beads into all corresponding serum-
containing wells of a 96-well KingFisher shallow-well plate. A ThermoScientific 
KingFisher Flex magnetic particle processor was used to transfer the BChE antibody-
conjugated magnetic beads to the wells containing filtered serum. BChE protein was bound 
to antibody-conjugated magnetic beads by shaking with an Eppendorf MixMate at 1400 rpm 
for 45 min at room temperature. The KingFisher was then used to transfer the protein-bound 
beads through three deep-well wash plates containing 500 μL PBST, and then to a 96-well 
KingFisher shallow-well digestion plate. Each well of the digestion plate contained 10 μL of 
2 mg/mL pepsin and 10 μL of 500 ng/mL isotopically labeled internal standard solution to 
give a final internal standard concentration of 58.8 ng/mL for BChE* and oCP-BChE*. The 
digestion plate also contained 75 μL of calibrator solution (2, 4, 8, 16, 32, 63, 125, or 150 
ng/mL of BChE and oCP-BChE synthetic peptides) or 75 μL of 0.6% formic acid for QC 
and matrix blank samples. The digestion plate was maintained at 37 °C and mixed at 1000 
rpm for 10 s per min for 30 min on an Eppendorf Thermomixer. Following digestion, the 
KingFisher was used to remove beads from the sample. Acetonitrile aliquots of 285 μL were 
added to a 0.2 μm filter, Pierce 2 mL protein precipitation plate. The digested samples were 
then manually added to the protein precipitation plate. A vacuum manifold was used to filter 
the samples through the protein precipitation plate and into a 96-well KingFisher deep-well 
plate. Samples were then dried to completeness under nitrogen pressure at 60 °C. Dried 
samples were resuspended in 75 μL of 0.6% formic acid for MS analysis.
UHPLC-MS/MS
BChE and oCP-BChE levels were determined in human serum using an Agilent 1290 
Infinity LC system coupled with an Agilent 6490 Triple Quadrupole mass spectrometer 
(Agilent, Santa Clara, CA). The mass spectrometer utilized a jet stream ionization interface, 
with sample analysis conducted in positive ionization mode. The instrument was tuned and 
calibrated bimonthly over a mass range of m/z 50–1400, using the Agilent ESI tuning 
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mixture (P/N G1969). Samples (3 μL) were injected onto a Waters Acquity UPLC HSS PFP 
column (1.8 μm, 1.0 mm × 50 mm) (Waters, Milford, MA). Column compartment 
temperature was set to 60 °C, and autosampler temperature was 10 °C. Mobile phases 
consisted of 0.1% formic acid in (A) water and (B) acetonitrile. Gradient conditions 
increased mobile phase B concentration from 2% to 60% over 1.33 min, followed by a 
reequilibration of the chromatograph at 2% B for 0.66 min, producing a total analysis time 
of 2 min per sample. Flow rate was held constant at 300 μL/min. The following parameters 
were used with the jet stream ionization source: drying gas temperature = 225 °C; drying gas 
flow = 11 L/min; nebulizer = 60 psi; sheath gas temperature = 350 °C; sheath gas flow = 11 
L/min; capillary voltage = 6000 V; nozzle voltage = 2000 V; iFunnel high pressure RF = 210 
V; iFunnel low pressure RF = 120 V; fragmenter voltage = 250 V. The mass spectrometer 
was operated in dynamic multiple reaction monitoring mode at “unit” resolution of 0.7 amu 
full width at half-maximum height, with a cycle time of 100 ms. Detection of BChE peptides 
used the following parameters: BChE quantitation ion m/z 796.3 → 691.3, collision energy 
= 25 V, cell accelerator voltage = 2.5 V. BChE confirmation ion m/z 796.3 → 620.3, 
collision energy = 27 V, cell accelerator voltage = 2.5 V. BChE* m/z 805.4 → 700.3, 
collision energy = 25 V, cell accelerator voltage = 2.5 V. Detection of oCP-BChE peptides 
used the following parameters: oCP-BChE quantitation ion m/z 966.4 → 778.3, collision 
energy = 34 V, cell accelerator voltage = 5 V. oCP-BChE confirmation ion m/z 966.4 → 
673.3, collision energy = 36 V, cell accelerator voltage = 7 V. oCP-BChE* standard m/z 
975.4 → 787.4, collision energy = 34 V, cell accelerator voltage = 5 V.
Data Acquisition and Processing
Data were acquired using MassHunter Workstation Software, LC/MS Data Acquisition for 
6400 Series Triple Quadrupole v. B.06.00, Build 6.0.6025.3 SP3. Spectral analysis and 
quantitation were carried out utilizing MassHunter Workstation Software Quantitative 
Analysis v. B.06.00 SP01, build 6.0.388.1. Accuracy was reported as percent relative error, 
% RE, where Ce is the experimental concentration determined from the calibration curve, 
and Ct is the theoretical concentration:
The percentage relative standard deviation, % RSD, was calculated as a measure of assay 
precision, where Cavg is the average calculated concentration and SD is the standard 
deviation.
Peak area ratios of BChE/BChE* and oCP-BChE/oCP-BChE* peptides were plotted against 
the expected concentration to construct calibration curves from eight BChE and oCP-BChE 
peptide calibrators in matrix blank serum. Each calibrator was injected (n = 32) and 
validated over the range of 2.0–150 ng/mL. QC material characterization was completed 
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over the course of 4 and a half weeks during method validation (n = 32) and performed by 
five laboratory analysts.
Safety considerations
The analysis of BChE and oCP-BChE peptides posed no greater risk to analysts than general 
peptide analyses. Universal safety precautions were followed for handling biological 
specimens such as blood products.
Results and Discussion
Detection and Separation
Fragmentation of synthetic BChE and BChE* peptides resulted in the predominant product 
ions m/z 691.3 and 700.3, respectively (Figure 1A and Supplemental Figure 1A). Likewise, 
fragmentation of synthetic oCP-BChE and oCP-BChE* peptides yielded the product ions 
m/z 778.3 and 787.4 (Figure 1B and Supplemental Figure 1B). Quantitation of BChE 
peptides was based on the transition m/z 796.3 → 691.3 and confirmation by transition m/z 
796.3 → 620.3. BChE* peptides were analyzed monitoring the transition m/z 805.4 → 
700.3. For oCP-BChE peptides, quantitation was based on the transition m/z 966.4 → 
778.3. This fragment was the result of β-elimination of oCP from Ser-198, yielding a 
dehydroalanine. To confirm the presence of oCP-BChE, the transition m/z 966.4 → 673.3 
was used, resulting from the loss of cresyl phosphate and collision induced fragmentation to 
the b8 ion. oCP-BChE* peptides were measured with transition m/z 975.4 → 787.4. A 
similar fragmentation pattern was previously reported for organophosphorus nerve agent 
adducts to BChE.30 In-source fragmentation was not observed for BChE, BChE*, oCP-
BChE or oCP-BChE* peptides.
A linear gradient of increasing mobile phase B concentration from 2% to 60% B over 1.3 
min was used for the reversed-phase UHPLC separation. Under these conditions the 
unadducted BChE peptide was retained for 0.66 min and the oCP-BChE peptide for 0.81 
min. To account for matrix effects expected in clinical sample analysis, calibrators were 
processed in a matrix blank serum with no reportable amounts of unadducted BChE (back-
calculated concentration of BChE in matrix blank serum was below the method’s lowest 
reportable limit). Extracted ion chromatograms collected for the matrix blank, lowest 
calibrator, and highest calibrator for each analyte are presented (Figure 2). The peak signal 
intensity of the lowest calibrator was 3 times higher than the matrix blank for the BChE 
peptide and 5 times higher for the oCP-BChE peptide.
To demonstrate the applicability of this assay for clinical sample analysis, extracted ion 
chromatograms of uninhibited human serum and human serum exposed to CBDP are 
presented in Supplemental Figures. The extracted ion chromatogram of unexposed BChE is 
shown, and no false-positive identification of oCP-BChE is observed (supplemental Figure 
2A). An extracted ion chromatogram of human serum spiked with CBDP (supplemental 
Figure 2B) shows the presence of the oCP-BChE peptide.
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Linearity
The peak area ratios of BChE/BChE* peptides were linearly proportional to the 
concentration of unadducted BChE over the range of 2.0–150 ng/mL with a coefficient of 
determination of R2 = 0.9934 and a line equation of y = 0.0090x (± 0.0005) + 0.0064 
(± 0.0047). Likewise, the peak area ratios of oCP-BChE/oCP-BChE* peptides were linearly 
proportional over the concentration range of 2.0–150 ng/mL. The reportable coefficient of 
determination of R2 = 0.9927 with a line equation of y = 0.0407x (± 0.0069) – 0.0237 
(± 0.0195). The reportable concentration range is consistent with methods used in the 
quantitation of organophosphorus nerve agent adducts to BChE in clinical samples and the 
abundance of unadducted BChE in the general population (40–80 nM in plasma).29–33 The 
Taylor calculation was used to determine the theoretical limit of detection (LOD) for BChE 
at 1.19 ng/mL.34 For oCP-BChE, the theoretical LOD was 1.89 ng/mL. The lowest 
calibrator for this method, 2.0 ng/mL, was the lowest reportable limit for both analytes (see 
Figure 2). This corresponded to an on-column mass of 6 pg based on a 3 μL injection 
volume. In 2014, Schopfer and coworkers reported a LOD of 4.0 ng/mL for oCP-BChE with 
a 5 μL injection volume.28 Based on the on-column injection mass, our method 
demonstrated a greater than 3-fold improvement in sensitivity. The enhanced sensitivity 
could be attributed to an efficient BChE purification technique and the use of a triple 
quadrupole mass spectrometer operated in multiple reaction monitoring mode.
Recovery and Matrix Effects
Ideally, an isotopically-labeled protein would be used to measure losses occurring during 
sample preparation; however, a protein standard is not currently available. Calibrator and 
internal standard peptides were added at the earliest possible step since anti-BChE beads 
would not capture calibrators. To assess the extraction efficiency of BChE and oCP-BChE 
peptides during sample preparation, calibrators were added to matrix blank serum either 
before pepsin digestion (“Processed”) or immediately prior to UHPLC-MS/MS analysis 
(“Unprocessed”). The “Processed” samples were representative of the sample preparation 
technique used for peptide calibrators in this analysis. The average peak areas (n = 4) from 
processed and unprocessed samples were used to calculate recovery. As shown in Table 1, 
recovery for both analytes was measured at low, mid, and high calibrator levels. The mean 
percentage recovery was ≥ 65% for BChE and ≥ 70% for oCP-BChE peptides. A few 
potential sources of sample loss include nonspecific pepsin digestion and peptide adsorption 
to plastic surfaces.35
Matrix effects were evaluated by comparing the average peak areas of “unprocessed” 
calibrators in matrix blank serum and in solvent solution. Matrix effects for BChE were 
evaluated using the highest calibrator (150. ng/mL) so that the contribution of endogenous 
BChE in the matrix blank would be less than 1% of the peak area. The ion suppression of 
BChE from matrix effects was determined to be 8%. For oCP-BChE, matrix effects 
accounted for an approximate 17% reduction in mean peak area.
Stability and Ruggedness
The effects of storage were evaluated by measuring peak area ratios of BChE/BChE* 
peptides and oCP-BChE/oCP-BChE* peptides following cycles of freeze-thaws from 
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−70 °C to 22 °C. Synthetic BChE and oCP-BChE calibrators were subjected to 13 freeze-
thaw cycles in order to evaluate long-term storage and use. Both BChE and oCP-BChE 
peptides were found to be stable ± 10% of theoretical concentration. Stability of internal 
standards were also evaluated, with BChE* and oCP-BChE* peptides subjected to 50 freeze-
thaw cycles. The peak area of each internal standard was measured and found to be stable 
with a %RSD ≤ 10%.
To assess temperature effects on the analytical response ratio of BChE and oCP-BChE 
calibrators, peptides were allowed to stand for 0, 4, 8, and 24 hours at 4, 22, and 37 °C prior 
to UHPLC-MS/MS analysis. The average response ratios (n = 4) obtained at successive time 
points are presented in Figure 3. All mean values were within ± 10% of the initial value for 
up to 24 hours at all temperatures for BChE and oCP-BChE; however, variability of the 
oCP-BChE calibrator does increase at the 24 hour mark (RSD approaching 20%), indicating 
peptides should be stored at or below −20 °C when not in use.
The effects of storage were also evaluated for QC materials. Unexposed pooled serum (QC 
mid for BChE) and CBDP-inhibited serum (QC low for oCP-BChE) were allowed to stand 
for 0, 4, 8, 24, 48, and 72 hours at 4, 22, and 37 °C prior to UHPLC-MS/MS analysis. In 
unexposed pooled serum, BChE was found to be stable at all three temperatures for at least 
72 hours. The mean BChE concentration at each time/temperature point (n = 4 for each) was 
found to be within two standard deviations of the BChE concentration determined during 
QC characterization (see Accuracy and Precision). For CBDP-inhibited serum, oCP-BChE 
was found to be stable at all temperatures for at least 72 hours. The mean oCP-BChE 
concentration was within two standard deviations of the oCP-BChE concentration 
determined during QC characterization (see Accuracy and Precision) for each time/
temperature point (n = 4 for each). A previous study stated the oCP-BChE adduct is 
unstable; however our results demonstrate oCP-BChE in serum is stable for at least 3 days at 
4, 22 and 37 °C.36 Differences in sample preparation and analysis techniques could account 
for differences in adduct stability.
Ruggedness testing was conducted by evaluating changes in the following analysis 
parameters: column temperature, collision energy, slope of the LC gradient, LC flow rate 
and analytical column lot (3 different product lots tested). Evaluation was based on the 
calculated concentration accuracy for each analyte when ruggedness parameters were 
individually changed to ±10% of the optimized value. For example, the assay’s 60 °C 
column temperature was also evaluated at 54 °C and 66 °C. Accuracy was found to be 
within ±15% of the theoretical concentration when column temperature, LC gradient slope, 
and LC flow rate were examined above and below the method’s optimized settings. The use 
of LC columns from multiple product lots showed no impact in assay accuracy. Changes to 
the collision energies of each analyte did show significant impact on method accuracy with 
error exceeding 20%.
Accuracy and Precision
The intraday and interday accuracy and precision for the quantitation of BChE and oCP-
BChE peptides were determined over four and a half weeks. Five analysts participated in 
method validation, analyzing 2 calibration curves and corresponding QCs per day (16 
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different days of analysis, 32 total runs). Data collected at the beginning, middle, and end of 
method validation are shown for 2.0 ng/mL (low-), 16 ng/mL (mid-), and 150 ng/mL (high-) 
level calibrators. The intraday % Error for BChE peptides was ≤ 7.8% for the low-, ≤ 4.1% 
for the mid-, and ≤ 4.4% for the high-level calibrators. Corresponding % RSDs were ≤ 14%, 
≤ 9.8%, and ≤ 6.9% at the low-, mid-, and high-level calibrators (Table 2). Likewise, the 
intraday % Error for oCP-BChE peptides was ≤ 16%, ≤ 10%, and ≤ 6.0% (Table 3). Intraday 
% RSD for oCP-BChE peptides was ≤ 13%, ≤ 5.8%, and ≤ 8.9%. Analysis of interday 
accuracy for BChE peptides demonstrated a % Error of ≤ 0.9%, ≤ 0.5%, and ≤ 3.3%, with 
corresponding interday % RSD of 9.5%, 6.8%, and 3.3%. For oCP-BChE peptides, the 
interday % Error was ≤ 8.9%, ≤ 5.8%, and ≤ 3.8%, and the resultant interday % RSD was 
9.9%, 5.4%, and 4.9%. The method’s accuracy and precision follow the guidelines in the 
FDA’s guidance for bioanalytical method validation and thus show applicability for the 
analysis of clinical samples.37
A low-, mid-, and high-level QC was used for each analyte covering the method’s 
calibration range. The BChE mid-level QC was pooled uninhibited serum. Our assay 
determined the mean concentration of BChE in the mid-level QC was 36.2 (±4.80) ng/mL 
with a RSD = 13% (n = 32). These results were in agreement with the measured BChE 
concentration from our analysis of a commercial convenience set and results obtained by 
Pantazides and coworkers.29 Synthetic BChE peptide spikes in matrix blank serum were 
used for QC samples near the upper and lower range of the calibration curve (accuracy ≥ 
96%, RSD < 15%). For oCP-BChE, the low-level QC was made by exposing pooled human 
serum to CBDP. The mean concentration of oCP-BChE in the exposed serum sample was 
12.2 (±1.83) ng/mL with a RSD = 15% (n = 32). Synthetic peptide spikes into matrix blank 
serum were used as mid- and high-level oCP-BChE QCs (accuracy ≥ 92%, RSD < 15%). 
The precision of QC materials compared favorably with other reported assays monitoring 
organophosphorus compound adduction to BChE.29,33,38
Application to Commercial Convenience Set
A convenience set of commercially available individual serum samples was purchased to 
assess levels of unadducted BChE and oCP-BChE, if any. The mean BChE concentration of 
the 96 samples analyzed was 37.7 ng/mL (± 10.7) with a range of 18.8 to 67.0 ng/mL. These 
results were similar to the mean BChE concentration reported by Pantazides and coworkers 
following analysis of 192 commercially-purchased serum samples.29 For oCP-BChE, all 
samples were found to be lower than the assay’s lowest reportable limit with no evidence of 
peaks detected.
Thus far, the +170 amu BChE adduct observed in this work has only been reported 
following in vitro reaction of BChE with CBDP.24–28 This suggests oCP-BChE can be used 
as a biomarker of CBDP exposure. Previous studies have used phosphoserine BChE as a 
biomarker of CBDP; however, this adduct is not specific to CBDP exposure alone. For 
example, the organophosphorus nerve agent tabun also adducts to BChE, and acid hydrolysis 
can yield the same phosphoserine adduct.39 Comparison of this method to previous reports 
for oCP adduct detection shows the current work yields a greater than 3-fold improvement in 
sensitivity based on the on-column injection mass of the adducted peptide. This method also 
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required 75% less sample volume than previously reported methods.27,28 This is significant 
when sample volume is limited, such as in the analysis of pediatric samples.
Conclusions
This method was developed to address the current need for a quantitative method to confirm 
human exposure to CBDP in clinical samples using the biomarker oCP-BChE. The oCP 
adduct was not observed in the commercial convenience set analyzed, and to-date has only 
been identified following the in vitro reaction of BChE with CBDP. The immunomagnetic-
UHPLC-MS/MS method provides quantitation of both unadducted BChE and oCP-BChE 
over a concentration range of 2.0 to 150 ng/mL. The sensitivity of this method is consistent 
with similar methodologies used in the detection of organophosphorus nerve agent adducts 
in serum. The assay demonstrated high intraday and interday accuracy and precision of 
calibration standards. Analysis of pooled uninhibited serum and CBDP-inhibited serum QC 
materials over four and half weeks demonstrated high assay precision in accordance with 
FDA guidance for bioanalytical methods. Our results also demonstrated the oCP-BChE 
adduct is stable in serum for at least 72 hours at 4, 22 and 37 °C. This work is the first 
quantitative high-throughput assay reported for the measurement of oCP-BChE in human 
serum.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Chemical structures and product ion mass spectra of the precursor ions of synthetic peptides 
(A) BChE ([M+H]+ m/z 796.3); (B) oCP-BChE ([M+H]+ m/z 966.4). Fragmentation spectra 
were collected scanning the mass range of m/z 500–1000, using a collision energy of 27 V 
for BChE and 34 V for oCP-BChE. The dashed lines for each structure denote the proposed 
sites of fragmentation. The peptide sequence shown is FGESAGAAS.
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Figure 2. 
Extracted ion chromatograms of matrix blank serum containing (A) No synthetic peptide; 
(B) 2 ng/mL BChE (6 pg injection); (C) 150 ng/mL BChE (450 pg injection); (D) No 
synthetic peptide; (E) 2 ng/mL oCP-BChE (6 pg injection); (F) 150 ng/mL oCP-BChE (450 
pg injection). Detection of BChE was based on the transition m/z 796.3 → 691.3. oCP-
BChE used transition m/z 966.4 → 778.3, and quantitation was calculated from the peak 
area response ratio of BChE/BChE* or oCP-BChE/oCP-BChE*. The dashed lines indicate 
the chromatographic peak height.
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Figure 3. 
Stability of BChE and oCP-BChE peptide calibration standards in 0.1% formic acid buffer at 
(-■-) 4 °C, (-▲-) 22 °C and (-●-) 37 °C. The peptides were incubated at the desired 
temperature for (-◆-) 0, 4, 8 and 24 hours. Following incubation, peptides were added to 
matrix blank serum just prior to pepsin digestion. The calculated BChE and oCP-BChE 
concentrations and % peptide remaining is plotted (n=4); error bars represent ±SD.
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Scheme 1. 
Metabolism of ToCP and Formation of the o-Cresyl Phosphoserine (oCP) Adduct on Human 
BChE Active Site Serine-198
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